Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Postmarketing Office To Expand Research; New Deputy Director Is Honig

This article was originally published in The Tan Sheet

Executive Summary

The Center for Drug Evaluation & Research Office of Postmarketing Drug Risk Assessment will seek to increase its research base in its budget proposal for the fiscal year beginning Oct. 1.
Advertisement

Related Content

Merck Builds Risk Management Into Drug Development; Hires FDA’s Honi
Merck Builds Risk Management Into Drug Development; Hires FDA’s Honi
FDA Senior Scientist Schwetz To Chair Deputy Commissioner Search Cmte.
FDA Senior Scientist Schwetz To Chair Deputy Commissioner Search Cmte.
FDA Postmarketing Active Surveillance Pilot To Study Adverse Event Signals

Topics

Advertisement
UsernamePublicRestriction

Register

PS090277

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel